Transcatheter Versus Surgical Approach for the Treatment of Aortic Stenosis in Patients With Concomitant Coronary Artery Disease: A Systematic Review and Meta‐Analysis
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.31697 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Zaryab Bacha und 14 weiteren Autor:innen. Beteiligte Einrichtung: Khyber Medical College, Peshawar, Pakistan. Hauptthemen laut MEDLINE: Coronary Artery Disease, Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Aortic stenosis (AS) with concomitant coronary artery disease (CAD) requires an approach that addresses both valvular and coronary pathology. While surgical aortic valve replacement (SAVR) with coronary artery bypass graft (CABG) has long been the standard treatment, transcatheter aortic valve replacement (TAVI) with percutaneous coronary intervention (PCI) has become a less invasive alternative. This meta‐analysis compares the clinical outcomes of TAVI + PCI versus SAVR + CABG in patients with AS and concomitant CAD. A systematic review and meta‐analysis were conducted according to PRISMA guidelines. Fourteen studies, including two randomized controlled trials (RCTs) and 12 observational studies, with a total of 187,189 patients (31,298 in the TAVI + PCI group and 155,891 in the SAVR + CABG group) were included. Outcomes analyzed included 30‐day mortality, stroke, major adverse cardiovascular and cerebrovascular events (MACCE), coronary reintervention, atrial fibrillation, major bleeding, vascular complications, acute kidney injury (AKI), perioperative myocardial infarction MI), permanent pacemaker implantation (PPI), length of hospital stay, and long‐term survival. Patients undergoing TAVI + PCI were generally older (ranging from 76.3 ± 3.7 to 83.6 ± 3.7 years) and had higher rates of chronic kidney disease (CKD) compared to the SAVR + CABG group. Other comorbidities, such as diabetes and hypertension, were comparable between groups. The EuroSCORE varied widely (3 ± 2.2 to 36.1 ± 18.1), reflecting a mix of surgical risk profiles. TAVI + PCI was associated with a lower 30‐day mortality rate (OR: 0.63, 95% CI: 0.37–1.07, p = 0.09), though the result was not statistically significant. Stroke rates were comparable between the two groups (OR: 0.89, 95% CI: 0.70–1.14, p = 0.36). There was no significant difference in MACCE (OR: 0.96, 95% CI: 0.50–1.84, p = 0.91). However, coronary reintervention was significantly higher in the TAVI + PCI group (OR: 4.32, 95% CI: 2.58–7.23, p < 0.00001). TAVI + PCI was associated with an 82% lower risk of atrial fibrillation (OR: 0.18, 95% CI: 0.11–0.30, p < 0.00001) but a similar risk of major bleeding (OR: 0.71, 95% CI: 0.38–1.31, p = 0.27). Vascular complications were significantly higher in the TAVI + PCI group (OR: 3.01, 95% CI: 1.52–5.93, p = 0.002), while perioperative AKI was lower (OR: 0.46, 95% CI: 0.21–0.99, p = 0.05). There was no significant difference in perioperative MI (OR: 0.78, 95% CI: 0.34–1.78, p = 0.55). However, TAVI + PCI was associated with a higher likelihood of PPI (OR: 2.14, 95% CI: 1.88–2.43, p < 0.00001). The length of hospital stay was significantly shorter in the TAVI + PCI group (mean difference: −3.45 days, 95% CI: −5.79 to −1.12, p = 0.004). Long‐term survival favored TAVI + PCI (OR: 0.63, 95% CI: 0.49–0.80, p = 0.0002). TAVI + PCI appears to be a viable alternative to SAVR + CABG, particularly in elderly or high‐risk patients, with advantages such as lower long‐term mortality, reduced atrial fibrillation, shorter hospital stays, and lower AKI rates. However, it carries a higher risk of coronary reintervention, vascular complications, and the need for PPI. These findings highlight the importance of individualized patient selection to balance risks and benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Khyber Medical College, Peshawar, Pakistan.
- Jinnah Sindh Medical University, Karachi, Pakistan.
- Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA.
- Department of Medicine, Mary Washington Healthcare, Fredericksburg, Virginia, USA.
- Rehman Medical College, Peshawar, Pakistan.
- All India Institute of Medical Sciences, Bhubaneswar, India.
ORCID-Profile: Fazia Khattak, Maria Qadri, Jishanth Mattumpuram, Shree Rath, Fathimathul Henna
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Bacha, Z., Javed, J., Khattak, F., Qadri, M., Shoaib, M., Shah, I. M., Khan, N. A., Ali, M. A., Mattumpuram, J., Tariq, M. D., Fakhar, M., Afridi, A., Kakakhel, M. Z., Rath, S., & Henna, F. (2025). Transcatheter Versus Surgical Approach for the Treatment of Aortic Stenosis in Patients With Concomitant Coronary Artery Disease: A Systematic Review and Meta‐Analysis. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31697
Vancouver
Bacha Z, Javed J, Khattak F, Qadri M, Shoaib M, Shah IM, et al. Transcatheter Versus Surgical Approach for the Treatment of Aortic Stenosis in Patients With Concomitant Coronary Artery Disease: A Systematic Review and Meta‐Analysis. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31697
BibTeX
@article{Bacha2025,
author = {Bacha, Zaryab and Javed, Javeria and Khattak, Fazia and Qadri, Maria and Shoaib, Muhammad and Shah, Izhar Muhammad and Khan, Naveed Ahmed and Ali, Muhammad Abdullah and Mattumpuram, Jishanth and Tariq, Muhammad Danyal and Fakhar, Mashal and Afridi, Abdullah and Kakakhel, Mian Zahid and Rath, Shree and Henna, Fathimathul},
title = {Transcatheter Versus Surgical Approach for the Treatment of Aortic Stenosis in Patients With Concomitant Coronary Artery Disease: A Systematic Review and Meta‐Analysis},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.31697}
}
EUVIMED